
Minerva Neurosciences (NERV) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Minerva Neurosciences to post earnings of -$0.17 per share. Last quarter,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| NERV | Minerva Neurosciences | 2.30 | -1.81 | -44.04% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.30 | -44.04% |

Minerva Neurosciences (NERV) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Minerva Neurosciences to post earnings of -$0.17 per share. Last quarter,

Jefferies upgraded Minerva (NERV) to Buy from Hold with a price target of $10, up from $7.50. The shares have sold despite the company’s execution, creating a favorable risk/reward ahead

Minerva Neurosciences ( ($NERV) ) just unveiled an announcement. On August 10, 2026, Minerva Neurosciences’ board appointed Vice President and Controller Anthony Aliquo as Chief Accounting Officer and principal accounting

Minerva Neurosciences (NERV) is scheduled to report 2nd quarter earnings on 08/04/2026. Regarding Q2 estimates, Wall Street analysts expect Minerva Neurosciences to post earnings of -$0.19 per share. Last quarter,

New option listings for July 22nd include Tradr 2X Short AAOI Daily ETF (AAOZ), Alpha Cognition Inc (ACOG), Bitzero Holdings Inc. Common Shares (AIBZ), Artiva Biotherapeutics Inc (ARTV), GlycoMimetics Inc

Meeting to be held in Boston on July 16 hosted by Citizens. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the

Minerva Neurosciences ( ($NERV) ) has provided an announcement. On June 3, 2026, Minerva Neurosciences held its 2026 annual meeting of stockholders, where investors approved amendments to its certificate of

Minerva Neurosciences ( ($NERV) ) has shared an announcement. On May 27, 2026, Minerva Neurosciences, Inc. entered into a sales agreement with Leerink Partners LLC to establish an at-the-market equity

Minerva Neurosciences ($NERV) announced an update on their ongoing clinical study. Minerva Neurosciences is running a Phase 3 study (NCT07565428) to test Roluperidone in adults with schizophrenia who have ongoing

H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on Minerva Neurosciences today and set a price target of $7.00. Douglas Tsao has given his Hold rating due to a
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 9, 2027TBA | $114.62M | $-0.17 | $0.00 | 0.00 | -0.09 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.